
Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Short Title: Momentous
Enrollment Status: Recruiting
NCT #: NCT06911632
Specialty Area: Pulmonology
Condition Studied: Interstitial Lung Disease (ILD) with Pulmonary Hypertension (PH)
Age Groups: Adult; Older Adult
Phase: Not Applicable
Study Information
Summary / Purpose
The goal of this study is to evaluate the use of an electrocardiogram (ECG)-based AI device that may help predict if participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension (PH).
Who Can Participate
- Adults 18+ years of age
- Diagnosed with interstitial lung disease
What's Involved
- Electrocardiogram (ECG), analyzed using an artificial intelligence (AI) tool designed to identify people who may be at higher risk for undiagnosed pulmonary hypertension
- Pulmonary function test
- Computed Tomography (CT) Imaging
- Blood sample
If identified as being at higher risk, undergo additional heart and lung evaluations, which may include:
- Echocardiogram (heart ultrasound)
- Right heart catheterization, a procedure used to assess heart function and measure pressures in the right side of the heart and pulmonary artery
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT06911632
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.